Skip to main content
. 2018 Sep 19;8(3):91–165. doi: 10.1016/j.kisu.2018.06.001

Figure 1.

Figure 1

Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and kidney transplant recipients (KTRs), by hepatitis C virus (HCV) genotypea. Duration of therapy for all above regimens is usually 12 weeks but readers should consult Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver guidelines for latest guidance. aWe recommend that CKD patients with glomerular filtration rates (GFRs) ≥ 30 ml/min per 1.73 m2 (CKD G1T–G3bT) be treated with any licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30 ml/min per 1.73 m2 (CKD G4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin inhibitors. cBased on Reau et al.3dAs suggested in AASLD guidelines (https://www.hcvguidelines.org/). CKD G, chronic kidney disease (GFR category); HD, hemodialysis; n/a, no data or evidence available; PD, peritoneal dialysis.